These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 19508388)

  • 1. Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence.
    Luetzkendorf J; Mueller LP; Mueller T; Caysa H; Nerger K; Schmoll HJ
    J Cell Mol Med; 2010 Sep; 14(9):2292-304. PubMed ID: 19508388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo.
    Mueller LP; Luetzkendorf J; Widder M; Nerger K; Caysa H; Mueller T
    Cancer Gene Ther; 2011 Apr; 18(4):229-39. PubMed ID: 21037557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.
    Yuan Z; Kolluri KK; Sage EK; Gowers KH; Janes SM
    Cytotherapy; 2015 Jul; 17(7):885-96. PubMed ID: 25888191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
    Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
    Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model.
    Mohr A; Lyons M; Deedigan L; Harte T; Shaw G; Howard L; Barry F; O'Brien T; Zwacka R
    J Cell Mol Med; 2008 Dec; 12(6B):2628-43. PubMed ID: 18373740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A therapeutic strategy for metastatic malignant fibrous histiocytoma through mesenchymal stromal cell-mediated TRAIL production.
    Lee HJ; Yang HM; Choi YS; Park SH; Moon SH; Lee YS; Sung YC; Kim SJ
    Ann Surg; 2013 May; 257(5):952-60. PubMed ID: 23108118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma.
    Lathrop MJ; Sage EK; Macura SL; Brooks EM; Cruz F; Bonenfant NR; Sokocevic D; MacPherson MB; Beuschel SL; Dunaway CW; Shukla A; Janes SM; Steele C; Mossman BT; Weiss DJ
    Cancer Gene Ther; 2015 Jan; 22(1):44-54. PubMed ID: 25525034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
    Mohr A; Albarenque SM; Deedigan L; Yu R; Reidy M; Fulda S; Zwacka RM
    Stem Cells; 2010 Nov; 28(11):2109-20. PubMed ID: 20882532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.
    Yu R; Deedigan L; Albarenque SM; Mohr A; Zwacka RM
    Cell Death Dis; 2013 Feb; 4(2):e503. PubMed ID: 23429289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.
    Grisendi G; Bussolari R; Cafarelli L; Petak I; Rasini V; Veronesi E; De Santis G; Spano C; Tagliazzucchi M; Barti-Juhasz H; Scarabelli L; Bambi F; Frassoldati A; Rossi G; Casali C; Morandi U; Horwitz EM; Paolucci P; Conte P; Dominici M
    Cancer Res; 2010 May; 70(9):3718-29. PubMed ID: 20388793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas.
    Nesterenko I; Wanningen S; Bagci-Onder T; Anderegg M; Shah K
    PLoS One; 2012; 7(11):e49219. PubMed ID: 23145127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRAIL-overexpressing Adipose Tissue-derived Mesenchymal Stem Cells Efficiently Inhibit Tumor Growth in an H460 Xenograft Model.
    Un Choi Y; Yoon Y; Jung PY; Hwang S; Hong JE; Kim WS; Sohn JH; Rhee KJ; Bae KS; Eom YW
    Cancer Genomics Proteomics; 2021; 18(4):569-578. PubMed ID: 34183389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma.
    Sage EK; Kolluri KK; McNulty K; Lourenco Sda S; Kalber TL; Ordidge KL; Davies D; Gary Lee YC; Giangreco A; Janes SM
    Thorax; 2014 Jul; 69(7):638-47. PubMed ID: 24567297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-γ-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway.
    Yang X; Du J; Xu X; Xu C; Song W
    J Immunol Res; 2014; 2014():318098. PubMed ID: 24971369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
    Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
    Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
    Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
    Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAIL-expressing gingival-derived mesenchymal stem cells inhibit tumorigenesis of tongue squamous cell carcinoma.
    Xia L; Peng R; Leng W; Jia R; Zeng X; Yang X; Fan M
    J Dent Res; 2015 Jan; 94(1):219-28. PubMed ID: 25391621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.
    Choi SA; Lee C; Kwak PA; Park CK; Wang KC; Phi JH; Lee JY; Chong S; Kim SK
    Cancer Lett; 2019 Feb; 442():161-169. PubMed ID: 30367915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma.
    Yulyana Y; Endaya BB; Ng WH; Guo CM; Hui KM; Lam PY; Ho IA
    Stem Cells Dev; 2013 Jul; 22(13):1870-82. PubMed ID: 23428290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.